HC Wainwright Issues Negative Estimate for PolyPid Earnings

PolyPid Ltd. (NASDAQ:PYPD) – HC Wainwright decreased their FY2029 earnings per share estimates for shares of PolyPid in a report released on Wednesday, August 12th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.75 for the year, down from their previous estimate of $0.80. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $1.57 EPS.

Several other brokerages have also recently issued reports on PYPD. Craig Hallum set a $12.00 target price on shares of PolyPid in a report on Wednesday, July 22nd. Weiss Ratings upgraded shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.33.

PolyPid Stock Up 2.3%

PYPD opened at $4.84 on Thursday. The firm has a 50 day moving average price of $4.74 and a 200-day moving average price of $4.57. PolyPid has a twelve month low of $3.06 and a twelve month high of $5.73. The stock has a market capitalization of $92.35 million, a price-to-earnings ratio of -2.53 and a beta of 1.41.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03.

Hedge Funds Weigh In On PolyPid

A number of hedge funds have recently modified their holdings of PYPD. BNP Paribas Financial Markets increased its stake in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares in the last quarter. HighTower Advisors LLC bought a new stake in PolyPid during the fourth quarter valued at about $44,000. XTX Topco Ltd lifted its position in shares of PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after acquiring an additional 10,888 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of PolyPid in the fourth quarter valued at about $66,000. Finally, Renaissance Technologies LLC bought a new position in shares of PolyPid in the first quarter worth about $81,000. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.